Advertisement

Influenza pp 291-345 | Cite as

The Control of Influenza

  • Edwin D. Kilbourne

Abstract

Influenza is essentially an uncontrolled disease. The effect of current vaccination programs on morbidity is insignificant, and that on mortality marginal. Although effective artificial immunization against influenza was demonstrated soon after the first isolation of the virus from man (Chenoweth et al., 1936), the antigenic variability of the virus has hampered vaccine production and precluded effective control (Table 11–1). The transient protection afforded by presently available inactivated virus vaccines is related, in part, to a rapid decline in vaccine-induced homologous antibody but also to vaccine obsolescence as the result of continuous viral mutation to antigens unlike or less like those of viral predecessors contained in the vaccine (Kilbourne, 1978).

Keywords

Influenza Virus Virus Vaccine Influenza Vaccine Influenza Vaccination Swine Influenza 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allan, W. H., Madeley, C. R., and Kendal, A. P., 1971, Studies with avian influenza A viruses: Cross protection experiments in chickens, J. Gen. Virol 12:79–84.PubMedCrossRefGoogle Scholar
  2. Anderson, R. M., and May, R. M., 1985, Vaccination and herd immunity to infectious diseases, Nature 318:323–329.PubMedCrossRefGoogle Scholar
  3. Anonymous, 1978, Influenza immunization in lupus erythematosus: Safe, effective? Ann. Intern. Med. 88:833–834.Google Scholar
  4. Armerding, D., Rossiter, H., Ghazzouli, I., et al., 1982, Evaluation of live and inactivated influenza A virus vaccines in a mouse model, J. Infect. Dis. 145:320–330.PubMedCrossRefGoogle Scholar
  5. Atassi, M. Z., and Webster, R. G., 1983, Localization, synthesis, and activity of an antigenic site on influenza virus hemagglutinin, Proc. Natl. Acad. Sci. U.S.A. 80:840–844.PubMedCrossRefGoogle Scholar
  6. Baez, M., Palese, P., and Kilbourne, E. D., 1980, Gene composition of high-yielding influenza vaccine strains obtained by recombination,J. Infect. Dis. 141:362–365.PubMedCrossRefGoogle Scholar
  7. Banks, J., Bevan, C., Fennerty, A., et al., 1985, Association between rise in antibodies and increase in airway sensitivity after intramuscular injection of killed influenza virus in asthmatic patients, Eur. J. Respir. Dis. 66:268–272.PubMedGoogle Scholar
  8. Barker, W. H., and Mullooly, J. P., 1980, Influenza vaccination of elderly persons, J.A.M.A. 244:2547–2549.PubMedCrossRefGoogle Scholar
  9. Barker, W. H., and Mullooly, J. P., 1982, Pneumonia and influenza deaths during epidemics: Implications for prevention, Arch. Intern. Med. 142:85–89.PubMedCrossRefGoogle Scholar
  10. Barry, D. W., Mayner, R. E., Hochstein, H. D., et al., 1976a, Comparative trial of influenza vaccines. II. Adverse reactions in children and adults, Am. J. Epidemiol. 104:47–59.PubMedGoogle Scholar
  11. Barry, D. W., Mayner, R. E., Staton, E., et al., 1976b, Comparative trial of influenza vaccines. I. Im-munogenicity of whole virus and split product vaccines in man, Am. J. Epidemiol. 104:34–46.PubMedGoogle Scholar
  12. Baskerville, A., Thomas, G., and Peacock, S., 1975, Pathological aspects of immunization of mice against influenza virus infection, Br. J. Exp. Pathol. 56: 17–27.PubMedGoogle Scholar
  13. Beare, A. S., 1975, Live viruses for immunization against influenza, Prog. Med. Virol. 20:49–83.PubMedGoogle Scholar
  14. Beare, A. S., and Bynoe, M. L., 1969, Attenuation of human influenza A viruses, Br. Med. J. 4:198–201.PubMedCrossRefGoogle Scholar
  15. Beare, A. S., Bynoe, M. L., and Tyrrell, D. A. J., 1968a, Investigation into the attenuation of influenza viruses by serial passage, Br. Med. J. 4:482–484.PubMedCrossRefGoogle Scholar
  16. Beare, A. S., Hobson, D., Reed, S. E., et al., 1968b, A comparison of live and killed influenza-virus vaccines, Lancet 2:418–420.PubMedCrossRefGoogle Scholar
  17. Beare, A. S., Schild, G. C., and Craig, J. W., 1975, Trials in man with live recombinants made from A/PR/8/34 (H0N1) and wild H3N2 influenza viruses, Lancet 2:729–738.PubMedCrossRefGoogle Scholar
  18. Becht, H., Huang, R. T. C., Fleisher, B., et al., 1984, Immunogenic properties of the small chain HA2 of the haemagglutinin of influenza viruses, J. Gen. Virol. 65:173–183.PubMedCrossRefGoogle Scholar
  19. Beebe, G. W., Simon, A. H., and Vivona, S., 1964, Follow-up study on army personnel who received adjuvant influenza virus vaccine, 1951–1953, Am. J. Med. Sci. 247:385–406.PubMedCrossRefGoogle Scholar
  20. Bell, T. D., Chai, H., Berlow, B., et al., 1978, Immunization with killed influenza virus in children with chronic asthma, Chest 73:140–145.PubMedCrossRefGoogle Scholar
  21. Bennink, J. R., Yewdell, J. W., Smith, G. L., et al., 1984, Recombinant vaccinia virus primes and stimulates influenza hemagglutinin-specific cytotoxic T cells, Nature 311:578–579.PubMedCrossRefGoogle Scholar
  22. Bernstein, D. I., and Cherry, J. D., 1983, Clinical reactions and antibody responses to influenza vaccines, Am. J. Dis. Child. 137:622–626.PubMedGoogle Scholar
  23. Bernstein, D. I., Zahradnik, J. M., DeAngelis, C. J., et al., 1982, Influenza immunization in children and young adults, Am. J. Dis. Child. 36:513–517.Google Scholar
  24. Betts, R. F., Douglas, R. G., Jr., Roth, F. K., et al., 1977, Efficacy of live attenuated influenza A/Scot-land/74 (H3N2) virus vaccine against challenge with influenza A/Victoria/3/75 (H3N2) virus, J. Infect. Dis. 136:746–753.PubMedCrossRefGoogle Scholar
  25. Beutner, K. R., Chow, T., Rubi, E., et al., 1979, Evaluation of a neuraminidase-specific influenza A virus vaccine in children: Antibody responses and effects on two successive outbreaks of natural infection, J. Infect. Dis. 140:844–850.PubMedCrossRefGoogle Scholar
  26. Bierman, C. W., Shapiro, G. G., Pierson, W. E., et al., 1977, Safety of influenza vaccination in allergic children, J. Infect. Dis. 136:S652–S655.PubMedCrossRefGoogle Scholar
  27. Biro, J., and Beregi, E., 1980, The influence of influenza vaccinations on human peripheral lymphocytes relating to aging, Akt. Gerontol. 10:319–322.Google Scholar
  28. Blumberg, S., Bienfang, D., and Kantrowitz, F. G., 1980, A possible association between influenza vaccination and small-vessel vasculitis, Arch. Intern. Med. 140:847–848.PubMedCrossRefGoogle Scholar
  29. Boffey, P. M., 1976, Swine flu campaign: Should we vaccinate the pigs? Science 192:870.PubMedCrossRefGoogle Scholar
  30. Both, G. W., Shi, C. H., and Kilbourne, E. D., 1983, Hemagglutinin of swine influenza virus: A single amino acid change pleiotropically affects viral antigenicity and replication, Proc. Natl. Acad. Sci. U.S.A. 80:6996–7000.PubMedCrossRefGoogle Scholar
  31. Brooks, R., and Reznik, A., 1980, Guillain-Barre syndrome following trivalent influenza vaccine in an elderly patient, Mt. Sinai J. Med. 47:190–191.PubMedGoogle Scholar
  32. Brown, L. A., Dopheide, T. A. A., Ward, C. W., et al., 1980, Antigenic determinants of influenza virus hemagglutinin. V. Antigenicity of the HA2 chain, J. Immunol. 125:1583–1588.PubMedGoogle Scholar
  33. Bruyn, H. B., Meiklejohn, G., and Brainerd, H. D., 1949, Influenza vaccination: A comparison of antibody response obtained by various methods of administration, J. Immunol. 62:1–11.PubMedGoogle Scholar
  34. Buchner, D. M., Carter, W. B., and Inui, T. S., 1985, The relationship of attitude changes to compliance with influenza immunization, Med. Care 23:771–779.PubMedCrossRefGoogle Scholar
  35. Budnick, L. D., Stricof, R. L., and Ellis, F., 1984, An outbreak of influenza A in a nursing home, 1982, N.Y. State J. Med. 84:235–238.PubMedGoogle Scholar
  36. Bukowskyj, M., Munt, P. W., Wigle, R., et al., 1984, Theophylline clearance, Am. Rev. Respir. Dis. 129:672–675.PubMedGoogle Scholar
  37. Burlington, D. B., Wright, P. F., van Wyke, K. L., et al., 1985, Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children, J. Clin. Microbiol. 21:847–849.PubMedGoogle Scholar
  38. Burnet, F. M., 1943, Immunization against epidemic influenza with living attenuated virus, Med. J. Aust. 1:385–389.Google Scholar
  39. Buttar, K., Chernesky, M., and Dolovich, J., 1981, Cutaneous responses to tests with influenza vaccines, Ann. Allergy 46:183–188.PubMedGoogle Scholar
  40. Cannata, J., Cuesta, V., Peral, V., et al., 1981, Reactivation of vasculitis after influenza vaccination, Br. Med. J. 83:526.CrossRefGoogle Scholar
  41. Caspary, E. A., Currie, S., Walton, J. N., et al., 1971, Lymphocyte sensitization to nervous tissues and muscle in patients with the Guillain-Barre syndrome, J. Neurol. Neurosurg. Psychiatry 34:179–181.PubMedCrossRefGoogle Scholar
  42. Centers for Disease Control, 1985a, Immunization Practices Advisory Committee, recommendations, Morbid. Mortal. Weekly Rep. 34:262–267.Google Scholar
  43. Centers for Disease Control, 1985b, Implementation of recommendations for influenza control, Morbid. Mortal. Weekly Rep. 34:639–643.Google Scholar
  44. Chenoweth, A., Waltz, A. D., Stokes, J., Jr., et al., 1936, Active immunization with the viruses of human and swine influenza, Am. J. Dis. Child. 52:757–758.Google Scholar
  45. Clark, A., Potter, C. W., Jennings, R., et al., 1983, A comparison of live and inactivated influenza A (H1N1) virus vaccines, J. Hyg. (Camb.) 90:361–370.CrossRefGoogle Scholar
  46. Clements, M. L., and Murphy, B. R., 1986, Development and persistence of local systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine, J. Clin. Microbiol. 23:66–72.PubMedGoogle Scholar
  47. Clements, M. L., O’Donnell, S., Levine, M. M., et al., 1983, Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: Role of local antibody in resistance to infection with vaccine virus, Infect. Immun. 40:1044–1051.PubMedGoogle Scholar
  48. Clements, M. L., Betts, R. F., Maassab, H. F., et al., 1984a, Dose response of influenza A/Washing-tonJ897J80 (H3N2) cold-adapted reassortment virus in adult volunteers, J. Infect. Dis. 149:814.PubMedCrossRefGoogle Scholar
  49. Clements, M. L., Betts, R. F., and Murphy, B. R., 1984b, Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection, Lancet 1:705.PubMedCrossRefGoogle Scholar
  50. Clements, M. L., Betts, R. F., Tierney, E. L., et al., 1986, Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine, J Clin. Microbiol. 23:73–76.PubMedGoogle Scholar
  51. Cole, P. J., and Molyneux, M. E., 1980, Immunological sensitization of human lymphocytes after influenza vaccination, J Infect. 2:67–77.PubMedCrossRefGoogle Scholar
  52. Cook, S. D., Dowling, P. C., and Whitaker, J. N., 1970, The Guillain-Barre syndrome, Arch. Neurol. 22:470–474.PubMedCrossRefGoogle Scholar
  53. Couch, R. B., Douglas, R. G., Fedson, D. S., et al., 1971, Correlated studies of a recombinant influenza-virus vaccine. III. Protection against experimental influenza in man, J. Infect. Dis. 124:473–480.PubMedCrossRefGoogle Scholar
  54. Couch, R. B., Kasel, J. A., Gerin, J. L., et al., 1974, Induction of partial immunity to influenza by a rieuramirridase-specificvaccine, J Infect. Dis. 129:411–420.PubMedCrossRefGoogle Scholar
  55. Couch, R. B., Webster, R. G., Kasel, J. A., et al., 1979, Efficacy of purified influenza subunit vaccines and relation to the major antigenic determinants on the hemagglutinin molecule, J. Infect. Dis. 140:553–559.PubMedCrossRefGoogle Scholar
  56. Cox, N. J., and Kendal, A. P., 1984, Genetic stability of A/Ann Arbor/6/60 cold-mutant (temperature-sensitive) live influenza virus genes: Analysis by oligonucleotide mapping of recombinant vaccine strains before and after replication in volunteers, J. Infect. Dis. 149:194–200.PubMedCrossRefGoogle Scholar
  57. Cox, N. J., Kendal, A. P., Shilov, A. A., et al., 1985, Comparative studies of A/Leningrad/134/57 wild-type and 47-times passaged cold-adapted mutant influenza viruses: Oligonucleotide mapping and RNA-RNA hybridization studies, J. Gen. Virol. 66:1697–1704.PubMedCrossRefGoogle Scholar
  58. Crawford, C. R., Jennings, R., Bradford, N., et al., 1982, The effect of bacterial peptidoglycans on the immune response of hamsters to influenza virus vaccines, Clin. Exp. Immunol. 48:739–746.PubMedGoogle Scholar
  59. Crawford, C. R., Faiza Mukhlis, F. A., Jennings, R., et al., 1984, Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1. Preparation and characterization of disrupted virions, Vaccine 2: 193–198.PubMedCrossRefGoogle Scholar
  60. Davenport, F. M. 1961, Applied immunology of mineral oil adjuvants, J. Allergy 32:177–189.CrossRefGoogle Scholar
  61. Davis, A. R., Bos, T., Ueda, M., et al., 1983, Immune response to human influenza virus hemagglutinin expressed in Escherichia coli, Gene 21:273–284.PubMedCrossRefGoogle Scholar
  62. Dierckx, J. P., Raindorf, M., and Gillard, C., 1976, Surveillance da la fonction respiratoire chez des sujects souffrant de bronchopathie chronique, vaccines par une souche vivante attenuee de virus grippal (RIT 4025), Acta Tuberc, Pneumon. Belg. 67:23–31.Google Scholar
  63. Dolin, R., Wise, T. G., Mazur, M. H., et al., 1977, Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults, J. Infect. Dis. (Suppl.) 136:435–442.Google Scholar
  64. Dolin, R., Reichman, R. C., Madore, H. P., et al., 1982, A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection, N. Engl J. Med. 307:580–584.PubMedCrossRefGoogle Scholar
  65. Dowdle, W. R., 1977, The swine flu vaccine program, Am. Soc. Microbiol News 43:243–246.Google Scholar
  66. Dowdle, W. R., Millar, J. D., Schonberger, L. B., et al., 1980, Influenza immunization policies and practices in Japan, J. Infect. Dis. 141:258–264.PubMedCrossRefGoogle Scholar
  67. Downie, J. C., 1984, A genetic and monoclonal analysis of high-yielding reassortants of influenza A virus used for human vaccines, J. Biol. Stand. 12:101–110.PubMedCrossRefGoogle Scholar
  68. Dreesman, G. R., and Kennedy, R. C., 1985, Anti-idiotypic antibodies: Implications of internal image-based vaccines for infectious diseases, J. Infect. Dis. 151:761–765.PubMedCrossRefGoogle Scholar
  69. Dull, W. L., Seria, J., Bloomfield, J., et al., 1980, Effects of influenza vaccination on pulmonary function, Bull Eur. Physiopathol. Respir. 16:655–661.PubMedGoogle Scholar
  70. Dunn, G. F. N., and Wormald, P. J., 1973, Influenza-A Hong-Kong vaccine and the new variant A/ENG/42/72, Lancet 1:95.PubMedCrossRefGoogle Scholar
  71. Ennis, R. A., Dowdle, W. R., Barry, D. W., et al., 1977a, Endotoxin content and clinical reactivity to influenza vaccines, J. Biol. Stand. 5:165–172.PubMedCrossRefGoogle Scholar
  72. Ennis, F. A., Mayner, R. E., Barry, D. N., et al., 1977b, Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines, J. Infect. Dis. 136:S397–406.PubMedCrossRefGoogle Scholar
  73. Ennis, F. A., Yi-Hua, Q., and Schild, G. C., 1982, Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines, J. Gen. Virol 58:273–281.PubMedCrossRefGoogle Scholar
  74. Erickson, A. H., 1977, Different trypsin-sensitivity of the hemagglutinin from antigenically similar recombinant influenza vaccines, Doctoral dissertation, The City University of New York.Google Scholar
  75. Evans, A. S., and Kraus, G., 1978, Immunization against swine influenza in the Yale University community, Yale J. Biol. Med. 51:165–176.PubMedGoogle Scholar
  76. Fedson, D. S., and Kessler, H. A., 1983, A hospital-based influenza immunization program, 1977–78, Am. J. Public Health 73:442–445.PubMedCrossRefGoogle Scholar
  77. Felix, J. K., Schwartz, R. H., and Myers, G. J., 1976, Isolated hypoglossal nerve paralysis following influenza vaccination, Am. J. Dis. Child. 130:82–83.PubMedGoogle Scholar
  78. Fell, P. J., O’Donnell, H. F., Watson, N. P., et al., 1977, Longer term effects of live influenza vaccine in patients with chronic pulmonary disease, Lancet 1:1282–1284.PubMedCrossRefGoogle Scholar
  79. Foy, H. M., Cooney, M., McMahan, R., et al., 1969, A field trial of Hong Kong-strain influenza vaccine in Seattle schoolchildren, Bull WHO 41:564–566.PubMedGoogle Scholar
  80. Francis, T., Pearson, H. E., Salk, J. E., et al., 1944, Immunity in human subjects artificially infected with influenza virus, type B, Am. J. Public Health 34:317–334.CrossRefGoogle Scholar
  81. Frank, A. L., Webster, R. G., Glezen, W. P., et al., 1981, Immunogenicity of influenza A/USSR (H1N1) subunit vaccine in unprimed young adults, J. Med. Virol 7:135–142.PubMedCrossRefGoogle Scholar
  82. Ganz, P. A., Shanley, J. D., and Cherry, J. D., 1978, Responses of patients with neoplastic diseases to influenza virus vaccine, Cancer 42:2244–2247.PubMedCrossRefGoogle Scholar
  83. Gaydos, J. C., Hodder, R. A., Top, F. H., et al., 1977a, Swine influenza at Fort Dix, New Jersey (January-February 1976). I. Case finding and clinical study of cases, J. Infect. Dis. 136:S356–S362.PubMedCrossRefGoogle Scholar
  84. Gaydos, J. C., Hodder, R. A., Top, F. H., et al., 1977b, Swine influenza at Fort Dix, New Jersey (January-February 1976). II. Transmission and morbidity in units with cases, J Infect. Dis. 136:S363–S375.PubMedCrossRefGoogle Scholar
  85. Ghendon, Y. Z., Polezhaev, F. I., Lisovskaya, K. V., et al., 1984, Recombinant cold-adapted attenuated influenza A vaccines for use in children: Molecular genetic analysis of the cold-adapted donor and recombinants, Infect. Immun. 44:730–733.PubMedGoogle Scholar
  86. Goldfield, M., Bartley, J. D., Pizzuti, W., et al., 1977, Influenza in New Jersey in 1976: Isolations of influenza A/New Jersey/76 virus at Fort Dix, J. Infect. Dis. 136:S347–S355.PubMedCrossRefGoogle Scholar
  87. Gomolin, I. H., Chapron, D. J., and Luhan, P. A., 1985, Lack of effect of influenza vaccine on theophylline levels and warfarin anticoagulation in the elderly, J. Am. Geriatr. Soc. 33:269–272.PubMedGoogle Scholar
  88. Goodeve, A., Potter, C. W., Clark, A., et al., 1983, A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: Reactogenicity, antibody response and protection to challenge virus infection, J. Hyg. (Camb.) 90:107–115.CrossRefGoogle Scholar
  89. Goodeve, A. C., Jennings, R., and Potter, C. W., 1985, Reassortants of influenza B viruses for use in vaccines: An evaluation, Arch. Virol. 83:169–179.PubMedCrossRefGoogle Scholar
  90. Graves, P. N., Schulman, J. L., Young, J. F., et al., 1983, Preparation of influenza virus subviral particles lacking the HAl subunit of hemagglutinin: Unmasking of cross-reactive HA2 determinants, Virology 126:106–116.PubMedCrossRefGoogle Scholar
  91. Green, N., Alexander, H., Olson, A., et al., 1982, Immunogenic structure of the influenza virus hemagglutinin, Cell 28:477–487.PubMedCrossRefGoogle Scholar
  92. Greenstreet, R. L., 1984, Estimation of the probability that Guillain-Barre syndrome was caused by the swine flu vaccine: U.S. experience (1976–1977), Med. Sci. Law 24:61–67.PubMedGoogle Scholar
  93. Gremillion, D. H., Meiklejohn, G., Graves, P., et al., 1983, Efficacy of single-dose influenza immunization in Air Force recruits,J. Infect. Dis. 147:1099.PubMedCrossRefGoogle Scholar
  94. Gross, P. A., 1977, Reactogenicity and immunogenicity of bivalent influenza vaccine in one-and two-dose trials in children: A summary, J. Infect. Dis. 136:S616–S625.PubMedCrossRefGoogle Scholar
  95. Gross, P. A., Ennis, F. A., Gaerlan, P. F., et al., 1981, Comparison of new triton X-100 and tween-ether-treated split-product vaccines in children, J. Clin. Microbiol. 14:534–538.PubMedGoogle Scholar
  96. Gross, P. A., Gould, A. L., and Brown, A. E., 1985, Effect of cancer chemotherapy on the immune response to influenza virus vaccine: Review of published studies, Rev. Infect. Dis. 7:613–618.PubMedCrossRefGoogle Scholar
  97. Grossebauer, K., Langmaack, H., Schmidt, B., et al., 1969, Enhancement and neutralization of pyroge-nicity of influenza viruses by biologically active substances, Arch. Ges. Virusforsch. 28:151–164.CrossRefGoogle Scholar
  98. Gwaltney, J. M., DeSanctis, A. N., Metzgar, D. P., et al., 1977, Systematic reactions to influenza B vaccine. Am. J. Epidemiol. 105:252–260.PubMedGoogle Scholar
  99. Hackett, C. J., Taylor, P. M., and Askonas, B. A., 1983, Stimulation of cytotoxic T cells by liposomes containing influenza virus or its components, Immunology 49:255–263.PubMedGoogle Scholar
  100. Hackett, C. J., Hurwitz, J. L., Dietzschold, B., et al., 1985, A synthetic decapeptide of influenza virus hemagglutinin elicits helper T cells with the same fine recognition specificities as occur in response to whole virus, J. Immunol. 135:1391–1394.PubMedGoogle Scholar
  101. Hall, W. J., Douglas, R. G., Jr., Zaky, D. A., et al., 1976, Attenuated influenza virus in normal adults: Role of pulmonary function studies in vaccine trials, J. Infect. Dis. 133:145–152.PubMedCrossRefGoogle Scholar
  102. Halperin, W., Weiss, W. I., Altman, R., et al., 1979, A comparison of intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: Report of a study and review of the literature, Am. J. Public Health 69:1247–1251.PubMedCrossRefGoogle Scholar
  103. Hamzawi, J., Jennings, R., and Potter, C. W., 1981, Antigenicity in hamsters of inactivated vaccines prepared from recombinant influenza viruses, J. Hyg. (Camb.) 87:453–464.CrossRefGoogle Scholar
  104. Hasselbacher, P., 1977, Neuropathy after influenza vaccination, Lancet 1:551–552.PubMedCrossRefGoogle Scholar
  105. Helenius, A., and Simons, K., 1975, Solubilization of membranes by detergents, Biochim. Biophys. Acta 415:29.PubMedGoogle Scholar
  106. Henle, W., and Henle, G., 1945, Effects of adjuvants on vaccination of human beings against influenza, Proc. Soc. Exp. Biol. Med. 59:179–181.Google Scholar
  107. Herbert, A. A., Larke, R. P. B., and Markstad, E. L., 1979, Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease, J. Infect. Dis. 140:234–238.PubMedCrossRefGoogle Scholar
  108. Higashihara, M. 1975, Studies on genetic recombinants of influenza virus, Kitasato Arch. Exp. Med. 48:183–188.PubMedGoogle Scholar
  109. Hilleman, M. R., 1966, Critical appraisal of emulsified oil adjuvants applied to viral vaccines in: Progress in Medical Virology ,Volume 8 (J. L. Melnick, ed.), S. Karger, Basel, pp. 131–182.Google Scholar
  110. Hilleman, M. R., 1977, Serologic responses to split and whole swine influenza virus vaccines in light of the next influenza pandemic, J. Infect. Dis. 136:S683–S685.PubMedCrossRefGoogle Scholar
  111. Hirst, G. K., Rickard, E. R., Whitman, L., et al., 1942, Antibody response of human beings following vaccination with influenza viruses, J. Exp. Med. 75:495–511.PubMedCrossRefGoogle Scholar
  112. Hodder, R. A., Gaydos, J. C., Allen, R. G., et al., 1977, Swine influenza A at Fort Dix, New Jersey (January-February 1976). III. Extent of spread and duration of the outbreak, J. Infect. Dis. 136:S369–S375.PubMedCrossRefGoogle Scholar
  113. Hodges, G. R., Davis, J. W., Lewis, D., et al., 1979, Response to influenza A vaccine among high-risk patients, South. Med. J. 72:29–32.PubMedCrossRefGoogle Scholar
  114. Hoskins, T. W., 1977, Systemic reactions to influenza vaccine containing killed influenza A/.New Jersey/8/76, Practitioner 219:400–401.PubMedGoogle Scholar
  115. Hoskins, T. W., Davies, J. R., Allchin, A., et al., 1973, Controlled trial of inactivated influenza vaccine containing the A/Hong Kong strain during an outbreak of influenza due to the A/England/42/72 strain, Lancet 2:116–120.PubMedCrossRefGoogle Scholar
  116. Hoskins, T. W., Davies, J. R., Smith, A. J., et al., 1979, Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital, Lancet 1:33–35.PubMedCrossRefGoogle Scholar
  117. Houston, T. P., 1983, Small-vessel vasculitis following simultaneous influenza and pneumococcal vaccination, N.Y. State J. Med. 83:1182–1183.PubMedGoogle Scholar
  118. Hruskova, J., Syrucek, L., Zaradova, H., et al., 1978, Secretory antibody response to haemagglutinin of influenza virus A/Swine and A/Victoria in humans after administration of split and whole-virion vaccine, J. Biol. Stand. 6:181–185.PubMedCrossRefGoogle Scholar
  119. Hurwitz, E. S., Schonberger, L. B., Nelson, D. B., et al., 1981, Guillain-Barre syndrome and the 1978–1979 influenza vaccine, N. Engl. J. Med. 304:1557–1561.PubMedCrossRefGoogle Scholar
  120. Infectious Disease Branch, NIAID, 1976, Memo: Immunizations to protect individuals working with influenza virus, April 28, NIH, Bethesda.Google Scholar
  121. Iwasaki, T., and Nozima, T., 1977, Defense mechanisms against primary influenza virus infection in mice. I. The roles of interferon and neutralizing antibodies and thymus dependence of interferon and antibody production, J. Immunol. 118:256–263.PubMedGoogle Scholar
  122. Jennings, R., and Potter, C. W., 1973, Enhanced response to influenza A vaccines in hamsters primed by prior heterotype influenza infection, Arch. Ges. Virusforsch. 42:197–206.PubMedCrossRefGoogle Scholar
  123. Jennings, R., Smith, T. L., Spencer, R. C., et al., 1984, Inactivated influenza virus vaccines in man: A comparative study of subunit and split vaccines using two methods for assessment of antibody responses, Vaccine 2:75–80.PubMedCrossRefGoogle Scholar
  124. Jennings, R., Smith, T. L., Mellersh, A. R., et al., 1985, Antibody response and persistence in volunteers following immunization with varying dosages of a trivalent surface antigen influenza virus vaccine, J. Hyg. (Camb.) 94:87–95.CrossRefGoogle Scholar
  125. Johannsen, R., Moser, H., Hinz, J., et al., 1983, The quantification of the haemagglutinin content of influenza whole virus and Tween-ether split vaccines,J. Biol. Stand. 11:341–352.PubMedCrossRefGoogle Scholar
  126. Johnson, P. R., Feldman, S., Thompson, J. M., et al., 1985, Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine, J. Med. Virol. 17:325–335.PubMedCrossRefGoogle Scholar
  127. Journal of the American Medical Association ,1984, AMA offers recommendations for vaccine injury compensation, J.A.M.A. 252:2937–2946.CrossRefGoogle Scholar
  128. Kaplan, J. E., Katona, P., Hurwitz, E. S., et al., 1982, Guillain-Barre syndrome in the United States, 1979–1980 and 1980–1981, J.A.M.A. 248:698–700.PubMedCrossRefGoogle Scholar
  129. Kasel, J. A., Six, H. R., Couch, R. B., et al., 1979, Variant-specific antihemagglutinin serum response to type A influenza natural infection and inactivated vaccines in adults, Proc. Soc. Exp. Biol. Med. 161:519–521.PubMedGoogle Scholar
  130. Kava, T., and Laitinen, L. A., 1985, Effects of killed and live attenuated influenza vaccine on symptoms and specific airway conductance in asthmatics and healthy subjects, Allergy 40:42–47.PubMedCrossRefGoogle Scholar
  131. Kavet, J., 1972, Influenza and Public Health ,Masters thesis, Harvard School of Public Health, Boston.Google Scholar
  132. Kavet, J., 1976, Vaccine utilization: Trends in the implementation of public policy in the U.S.A., in: Influenza: Virus Vaccines Strategy (P. Selby, ed.), Academic Press, New York, pp. 297–308.Google Scholar
  133. Kendal, A. P., Goldfield, M., Noble, G. R., 1977a, Identification and preliminary antigenic analysis of swine influenza-like viruses isolated during an influenza outbreak at Fort Dix, New Jersey, J. Infect. Dis. 136:S381–S385.PubMedCrossRefGoogle Scholar
  134. Kendal, A. P., Noble, G. R., and Dowdle, W., 1977b, Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunological primed and unprimed populations, J. Infect. Dis. 136:S415–424.PubMedCrossRefGoogle Scholar
  135. Khan, M. W., Gallagher, M., Bucher, D., et al., 1982, Detection of influenza virus neuraminidase-specific antibodies by an enzyme-linked immunosorbent assay, J. Clin. Microsc. 16:115–122.Google Scholar
  136. Kilbourne, E. D., 1969, Future influenza vaccines and the use of genetic recombinants, Bull WHO 41:643–645.PubMedGoogle Scholar
  137. Kilbourne, E. D., 1976a, Op-ed page, New York Times ,February 13, p. 33.Google Scholar
  138. Kilbourne, E. D., 1976b, Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in the induction of anti-neuraminidase antibody in man, J. Infect. Dis. 134:384–394.PubMedCrossRefGoogle Scholar
  139. Kilbourne, E. D., 1977, Influenza pandemics in perspective, J.A.M.A. 237:1225–1228.PubMedCrossRefGoogle Scholar
  140. Kilbourne, E. D., 1978, Opinion: Influenza as a problem in immunology, J. Immunol. 120:1447–1452.PubMedGoogle Scholar
  141. Kilbourne, E. D., 1979, Swine flu: The virus that vanished, Human Nature 2:68–73.Google Scholar
  142. Kilbourne, E. D., 1984, Immunization strategy: Infection-permissive vaccines for the modulation of infection, in: Modern Approaches to Vaccines (R. M. Chanock and R. A. Lerner, eds.), Cold Spring Harbor Laboratory, New York, pp. 269–274.Google Scholar
  143. Kilbourne, E. D., 1985, Problems inherent in artificial immunization, Microbiology-1985, 243–246.Google Scholar
  144. Kilbourne, E. D., and Murphy, J. S., 1960, Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in ovo adaptation of early passage Asian strain isolates by combination with PR8. J. Exp. Med. 111:387–406.PubMedCrossRefGoogle Scholar
  145. Kilbourne, E. D., Laver, W. G., Schulman, J. L., et al., 1968, Antiviral activity of antiserum specific for an influenza virus neuraminidase. I. In vitro effects, J. Virol. 2:281–288.PubMedGoogle Scholar
  146. Kilbourne, E. D., Schulman, J. L., Schild, G. C., et al., 1971, Correlated studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine. J. Infect. Dis. 124:449–462.PubMedCrossRefGoogle Scholar
  147. Kilbourne, E. D., Chanock, R. M., Choppin, P. W., et al., 1974, Influenza vaccine: summary of influenza workshop V, J. Infect. Dis. 129:770–771.CrossRefGoogle Scholar
  148. Kilbourne, E. D., McGregor, S., and Easterday, B. C., 1981, Transmission of swine of hemagglutinin mutants of swine influenza virus, in: The Replication of Negative Strand Viruses (D. H. Bishop and R. W. Compans, eds.), Elsevier/North Holland, Amsterdam, pp. 449–453.Google Scholar
  149. Kilbourne, E. D., Gerhard, W., and Whitaker, C. W., 1983, Monoclonal antibodies to the hemagglutinin Sa antigenic site of A/PR/8/23 influenza virus distinguish biologic mutants of swine influenza virus, Proc. Natl. Acad. Sci. U.S.A. 80:6996–7000.PubMedCrossRefGoogle Scholar
  150. Klimov, A., Ghendon, Y., Zavadova, H., et al., 1983, High reproduction capacity of recombinants between H3N2 human influenza and fowl plague viruses is due to the gene coding for M proteins, Acta Virol. 27:434–438.PubMedGoogle Scholar
  151. Kramer, P., and McClain, C. J., 1981, Depression of aminopyrine metabolism by influenza vaccination, N Engl. J. Med. 305:1262–1264.PubMedCrossRefGoogle Scholar
  152. Kramer, P., Tsuru, M., Cook, C. E., et al., 1984, Effect of influenza vaccine on warfarin anticoagulation, Clin. Pharmacol. Ther. 35:416–418.PubMedCrossRefGoogle Scholar
  153. Kreuter, J., Mauler, R., Gruschkau, H., et al., 1976, The use of new polymethylmethacrylate adjuvants for split influenza vaccines, Exp. Cell Biol. 44:12–19.PubMedGoogle Scholar
  154. Kuwert, E. K., Werner, J., Scheiermann, N., et al., 1979, Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza. I. Hemagglutination inhibiting antibodies. Zentralbl. Bakteriol. Hyg. 244:155–174.Google Scholar
  155. Lamb, J. R., Eckels, D. D., Lake, P., et al., 1982, Human T-cell clones recognize chemically synthesized peptides of influenza hemagglutinin, Nature 300:66–69.PubMedCrossRefGoogle Scholar
  156. La Montagne, J. R., Noble, G. R., Quinnan, G. V., et al., 1983, Summary of clinical trials of inactivated influenza vaccine-1978, Rev. Infect. Dis. 5:723–736.PubMedCrossRefGoogle Scholar
  157. Lang, G., 1981, Turkey influenza vaccination. Vet. Rec. 108:425.PubMedCrossRefGoogle Scholar
  158. Langmuir, A. D., 1979, Guillain-Barre syndrome: The swine influenza virus vaccine incident in the United States of America, 1976–77: Preliminary communication, J. R. Soc. Med. 72:660–669.PubMedGoogle Scholar
  159. Langmuir, A. D., Bregman, D. J., Kurland, L. T., et al., 1984, An epidemiologic and clinical evaluation of Guillain-Barre syndrome reported in association with the administration of swine influenza vaccines,J. Epidemiol. 119:841–879.Google Scholar
  160. Lazzell, V., Waldman, R. H., Rose, C., 1984, Immunization against intluenza in humans using an oral enteric-coated killed virus vaccine, J. Biol. Stand. 12:315–321.PubMedCrossRefGoogle Scholar
  161. Leibovitz, A., Coultrip, R. L., Kilbourne, E. D., et al., 1971, Correlated studies of a recombinant influenza-virus vaccine. IV. Protection against naturally occurring influenza in military trainees, J. Infect. Dis. 124:481–487.PubMedCrossRefGoogle Scholar
  162. Lerman, S. J., Wright, P. F., and Patil, K. D., 1980, Antibody decline in children following A/New Jersey/76 influenza virus immunization, J. Pediatr. 96:271–274.PubMedCrossRefGoogle Scholar
  163. Levine, M., Jones, M. W., and Gribble, M., 1984, Increased serum phenytoin concentration following influenza vaccination, Clin. Pharm. 3:505–509.PubMedGoogle Scholar
  164. Lyons, J. E., 1976, The manufacturers’ role in the preparation of swine flu vaccine, in: Meeting of the New Jersey Public Health Association, June 23, Fort Dix, N.J.Google Scholar
  165. Maassab, H. F., 1967, Adaptation and growth characteristics of influenza virus at 25°C, Nature 213:612–614.PubMedCrossRefGoogle Scholar
  166. Maassab, H. F., Monto, A. S., and DeBorde, D. C., et al., 1981, Development of cold recombinants of influenza virus as live virus vaccines, in: Genetic Variation among Influenza Viruses (D. P. Nayak, ed.), ICN-UCLA Symposia on Molecular and Cellular Biology ,Vol. XXI, Academic Press, New York, pp. 617–637.Google Scholar
  167. Maassab, H. R., Kendal, A. P., Abrams, G. D., et al., 1982, Evaluation of a cold-recombinant influenza virus vaccine in ferrets, J. Infect. Dis. 146:780–790.PubMedCrossRefGoogle Scholar
  168. MacKenzie, J. S., 1977, Influenza subunit vaccine: Antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly, Br. Med. J. 1:200–202.PubMedCrossRefGoogle Scholar
  169. Macoul, K. L., 1982, Bilateral optic nerve atrophy and blindness following swine influenza vaccination, Ann. Ophthalmol. 14:398–399.PubMedGoogle Scholar
  170. MacPherson, B. V., Ashikaga, T., Dennis, S. M., et al., 1980, A cohort study of preventive health behavior: Swine flu vaccination acceptance in Vermont, Del. Med. J. 52:427–432.PubMedGoogle Scholar
  171. Marine, W. M., and Stuart-Harris, C., 1976, Reactions and serologic responses in young children and infants after administration of inactivated monovalent influenza A vaccine, J. Pediatr. 88:26–30.PubMedCrossRefGoogle Scholar
  172. Marine, W. M., and Thomas, J. E., 1979, Antigenic memory to influenza A viruses in man determined by monovalent vaccines, Postgrad. Med. J. 55:98–108.PubMedCrossRefGoogle Scholar
  173. Massicot, J. G., Murphy, B. R., Thierry, F., et al., 1980a, Temperature-sensitive mutants of influenza virus, Virology 101:242–249.PubMedCrossRefGoogle Scholar
  174. Massicot, J. G., Murphy, B. R., Van Wyke, K., et al., 1980b, P1 and P3 genes are responsible for satisfactory level of attenuation of ts-142 recombinants bearing H1N1 or H3N2 surface antigens of influenza A virus, Virology 106:187–190.PubMedCrossRefGoogle Scholar
  175. Masurel, N., Ophof, P., and dejong, P., 1981, Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus, J. Hyg. (Camb.) 87:201–209.CrossRefGoogle Scholar
  176. Matzkin, H., and Nili, E., 1984, Accidental tenfold overdose of influenza A vaccine: A clinical and serological study, Isr. J. Med. Sci. 20:411–415.PubMedGoogle Scholar
  177. McCahon, D., and Schild, G. C., 1972, Segregation of antigenic and biological characteristics during influenza virus recombination, J. Gen. Virol. 15:73–77.PubMedCrossRefGoogle Scholar
  178. McCarroll, J. R., and Kilbourne, E. D., 1958, The equivalence of the subcutaneous and intradermal routes in immunization with Asiatic strain influenza vaccine, N. Engl. J. Med. 259:618–621.PubMedCrossRefGoogle Scholar
  179. McDonald, J. C., Zuckerman, A. J., Beare, A. S., et al., 1962, Trials of live influenza vaccine in the Royal Air Force, Br. Med. J. 1:1036–1042.PubMedCrossRefGoogle Scholar
  180. McLaren, C., Potter, C. W., and Jennings, R., 1974, Immunity to influenza in ferrets, Med. Microbiol. Immunol. 160:33–45.PubMedCrossRefGoogle Scholar
  181. McLean, I. W., Jr., Beard, D., Taylor, A. R., et al., 1945, The relation of antibody response in swine to dose of the swine influenza virus inactivated with formalin and with ultraviolet light, J. Immunol. 51:65–99.Google Scholar
  182. McMichael, A. J., Gotch, F., Cullen, P., et al., 1981, The human cytotoxic T cell response to influenza A vaccination, Clin. Exp. Immunol. 43:276–284.PubMedGoogle Scholar
  183. McMichael, A. J., Askonas, B. A., Webster, R. G., et al., 1982, B-cell or T-cell immunity? Immunol. Today 3:255–260.CrossRefGoogle Scholar
  184. Meiklejohn, G., 1958, Effectiveness of monovalent influenza A-prime vaccine during 1957 influenza A-prime epidemic, Am. J. Hyg. 67:237–249.PubMedGoogle Scholar
  185. Meiklejohn, G., 1961, Asian influenza vaccination: Dosage, routes, schedules of inoculation and reactions, Am. Rev. Respir. Dis. 83:175–177.PubMedGoogle Scholar
  186. Meiklejohn, G., Eickhoff, T. C., Graves, P., et al., 1978, Antigenic drift and efficacy of influenza virus vaccines, 1976–1977, J. Infect. Dis. 138:618–624.PubMedCrossRefGoogle Scholar
  187. Melchizedek, A. N., Wabuke-Bunoti, Taku, A., et al., 1984, Cytolytic T lymphocyte and antibody responses to synthetic peptides of influenza virus hemagglutinin, J. Immunol. 133:2194–2201.Google Scholar
  188. Meredith, C. G., Christian, C., Johnson, R. F., et al., 1985, Effects of influenza virus vaccine on hepatic drug metabolism, Clin. Pharmacol. Ther. 37:396–401.PubMedCrossRefGoogle Scholar
  189. Mihail, A., Popa, L. M., Petrescu, A., et al., 1981, Study of recombinants derived from autochthonous influenza virus type A strains, Rev. Roum, Med. Virol. 32:225–229.Google Scholar
  190. Miles, R., Potter, C. W., Clarke, A., et al., 1982, A comparative study of the reactogenicity and im-munogenicity of two inactivated influenza vaccines in children, J. Biol. Stand. 10:59–68.PubMedCrossRefGoogle Scholar
  191. Mills, J., and Chanock, R. M., 1971, Temperature-sensitive mutants of influenza virus. I. Behavior in tissue culture and in experimental animals, J. Infect. Dis. 123:145–157.PubMedCrossRefGoogle Scholar
  192. Mitchell, D. M., Fitzharris, P., Knight, R. A., et al., 1982, Kinetics of specific in vitro antibody production following influenza immunization, Clin. Exp. Immunol. 48:491–498.PubMedGoogle Scholar
  193. Monto, A. S., and Ross, H. W., 1979, Swine influenza vaccine program in the community: Acceptability, reactions and responses, Am. J. Public Health 69:233–237.PubMedCrossRefGoogle Scholar
  194. Monto, A. S., Miller, F. D., and Maassab, H. F., 1982, Evaluation of an attenuated, cold-recombinant influenza B virus vaccine, J. Infect. Dis. 145:57–64.PubMedCrossRefGoogle Scholar
  195. Morein, B., and Simons, K., 1985, Subunit vaccines against enveloped viruses: Virosomes, micelles and other protein complexes, Vaccine 3:83–93.PubMedCrossRefGoogle Scholar
  196. Mostow, S. R., Schoenbaum, S. C., Dowdle, W. R., et al., 1970, Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man, Am. J. Epidemiol. 92:248–256.PubMedGoogle Scholar
  197. Mostow, S. R., Dowdle, W. R., Schoenbaum, S. C., et al., 1973, Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation, Postgrad. Med. J. 49:152–158.PubMedCrossRefGoogle Scholar
  198. MRC Advisory Group on Pulmonary Function Tests in Relation to Live Influenza Vaccines, 1984, Trials of live attenuated influenza virus vaccine in patients with chronic obstructive airways disease, Br. J. Dis. Chest 78:236–247.CrossRefGoogle Scholar
  199. Muldoon, R. L., Stanley, E. D., and Jackson, G. G., 1976, Use and withdrawal of amantadine chemoprophylaxis during epidemic influenza A, Am. Rev. Respir. Dis. 113:487–491.PubMedGoogle Scholar
  200. Mumford, J., Wood, J. M., Scott, A. M., et al., 1983, Studies with inactivated equine influenza vaccine, J. Hyg. (Camb.) 90:385–395.CrossRefGoogle Scholar
  201. Murphy, B. R., and Chanock, R. M., 1985, Immunization against viruses, in: Virology (B. N. Fields, ed.), Raven Press, New York, pp. 349–370.Google Scholar
  202. Murphy, B. R., Chalhub, E. G., Nusinoff, S. R., et al., 1972, Temperature-sensitive mutants of influenza virus. II. Attenuation of ts recombinants for man, J. Infect. Dis. 126:170–178.PubMedCrossRefGoogle Scholar
  203. Murphy, B. R., Chalhub, E. G., Nusinoff, S. R., et al., 1973, Temperature sensitive mutants of influenza virus. III. Further characterization of the ts-l[E] influenza A recombinant, J. Infect. Dis. 128:479–487.PubMedCrossRefGoogle Scholar
  204. Murphy, B. R., Richman, D. D., Spring, S. B., et al., 1976, Use of temperature-sensitive mutants of influenza A virus as live virus vaccine strains: Evaluation in laboratory animals, adults and children, Postgrad. Med. 52:381–388.CrossRefGoogle Scholar
  205. Murphy, B. R., Markoff, L. J., Chanock, R. M., et al., 1980, Genetic approaches to attenuation of influenza A viruses for man, Phil. Trans. R. Soc. Lond. [Biol] 288:401–415.CrossRefGoogle Scholar
  206. Murphy, B. R., Buckler-White, A. J., London, W. T., et al., 1984, Avian-human reassortant influenza A viruses derived from mating avian and human influenza A viruses, J. Infect. Dis. 150:841–850.PubMedCrossRefGoogle Scholar
  207. Murphy, K. R., and Strunk, R. C., 1985, Safe administration of influenza vaccine in asthmatic children sensitive to egg proteins, J. Pediatr. 106:931–933.PubMedCrossRefGoogle Scholar
  208. Murray, D. L., Imagawa, D. T., Kada, D. M., et al., 1979, Antibody response to nonvalent A/New Jersey/8/76 influenza vaccine in pregnant women, J. Clin. Microbiol. 10:184–187.PubMedGoogle Scholar
  209. Murray, R., 1961, Some problems in the standardization and control of influenza vaccine in 1957, Am. Rev. Respir. Dis. 83:160–167.PubMedGoogle Scholar
  210. Nature ,1985, Editorial: Statutory compensation urged, 316:476–477.Google Scholar
  211. Nestorowicz, A., Tregear, G. W., Southwell, C. N., et al., 1985, Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites, Mol Immunol. 22:145–154.PubMedCrossRefGoogle Scholar
  212. Neustadt, R. E., and Fineberg, H. V., 1978, The Swine Flu Affair, Decision Making on a Slippery Disease. U. S. Department of HEW, Washington.Google Scholar
  213. Newton Dunn, G. F., and Wormald, P. J., 1973, Influenza A Hong Kong vaccine and the new variant A/Eng/42/72, Lancet 1:95.PubMedCrossRefGoogle Scholar
  214. Noble, G. R., Kaye, H. S., Kendal, A. P., et al., 1977, Age-related heterologous antibody responses to influenza virus vaccination, J. Infect. Dis. 136:S686–692.PubMedCrossRefGoogle Scholar
  215. Odagiri, T., DeBorde, D. C., and Maassab, H. F., 1982, Cold-adapted recombinants of influenza A virus in MDCK cells. I. Development and characterization of A/Ann Arbor/6/60x A/Alaska/6/77 recombinant viruses, Virology 119:82–95.PubMedCrossRefGoogle Scholar
  216. Odagiri, T., Smitka, C. W., and Maassab, H. G., 1983, Cold-adapted reassortants of influenza A virus in MDCK cells. II. Role of the temperature-sensitive property of cold-adapted reassortants in mice, Microbiol. Immunol. 27:203–206.PubMedGoogle Scholar
  217. O’Donoghue, J. M., Ray, C. G., Terry, D. W., Jr., et al., 1973, Prevention of nosocomial influenza infection with amantadine, Am. J. Epidemiol. 97:276–282.PubMedGoogle Scholar
  218. Ogra, P. L., Chow, T., Beutner, K. R., et al., 1977, Clinical and immunologic evaluation of neur-aminidase-specific influenza A virus vaccine in humans, J. Infect. Dis. 135:499–506.PubMedCrossRefGoogle Scholar
  219. Okuno, Y., and Nakamura, K., 1966, Prophylactic effectiveness of live influenza vaccine in 1965, Biken J. 9:89–95.PubMedGoogle Scholar
  220. Osborn, J. (ed.), 1977, Influenza in America, 1918–1976 9,Prodist, New York.Google Scholar
  221. Palese, P., and Schulman, J. L., 1976, RNA pattern of “swine” influenza virus isolated from man is similar to those of other swine influenza viruses, Nature 263:528–530.PubMedCrossRefGoogle Scholar
  222. Panicali, D., Davis, S. W., Weinberg, R. L., et al., 1983, Construction of live vaccines by using genetically engineered poxviruses: Biological activity of recombinant vaccinia virus expressing influenza virus haemagglutinin, Proc. Natl. Acad. Sci. U.S.A. 80:5364.PubMedCrossRefGoogle Scholar
  223. Paoletti, E., Weinberg, R. L., Davis, S. W., et al., 1984, Genetically engineered poxviruses: A novel approach to the construction of live vaccines, Vaccine 2:204–205.PubMedCrossRefGoogle Scholar
  224. Parkman, P. D., Hopps, H. E., Rastogi, S. C., et al., 1977, Summary of clinical trials of influenza virus vaccines in adults, J. Infect. Dis. 136:S722–730.PubMedCrossRefGoogle Scholar
  225. Patriarca, P. A., Kendal, A. P., Stricof, R. L., et al., 1983, Influenza vaccination and warfarin or theophylline toxicity in nursing-home residents, N. Engl. J. Med. 308:1601–1602.PubMedCrossRefGoogle Scholar
  226. Patriarca, P. A., Kater, N. A., Kendal, A. P., et al., 1984, Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A virus infections in nursing homes, An-timicrob. Agents Chemother. 26:101–103.Google Scholar
  227. Patriarca, P. A., Weber, J. A., Parker, R. A., et al., 1985, Efficacy of influenza vaccine in nursing homes, J.A.M.A. 253:1136–1139.PubMedCrossRefGoogle Scholar
  228. Payler, D. K., and Purdham, P. A., 1984, Influenza A prophylaxis with amantadine in a boarding school, Lancet 1:502–504.PubMedCrossRefGoogle Scholar
  229. Pearman, W. A., 1978, Participation in flu immunization projects: What can we expect in the future? Am. J. Public Health 68:674–675.PubMedCrossRefGoogle Scholar
  230. Pemberton, R. M., Jenning, R., and Smith, T. L., 1985, Morphology and antigenicity studies on reas-sortant influenza (H3N2) viruses for use in inactivated vaccines, J. Hyg. (Camb.) 94:229–239.CrossRefGoogle Scholar
  231. Perkins, F. T., 1972, Experience in the United Kingdom with oil adjuvant influenza vaccines, Ann. Allergy 30:288–291.PubMedGoogle Scholar
  232. Perry, H. D., Mallen, F. J., Grodin, R. W., et al., 1979, Reversible blindness in optic neuritis associated with influenza vaccination, Ann. Ophthalmol. 11:545–550.PubMedGoogle Scholar
  233. Petrescu, A., Cajal, N., Bronitki, A., et al., 1977, The experience of the Stefan S. Nicolau Institute of Virology in the preparation and administration of inactivated influenza vaccines applicable by nasal or oral route, Rev. Roum. Med. Virol. 28:213–217.Google Scholar
  234. Petrov, R. V., Zhdanov, V. M., Kabanov, V. A., et al., 1985, [Enhancement of the immune response to surface antigens of influenza virus as a result of their covalent binding with a synthetic carrier polymer], Biull. Eksp. Biol. Med. 99:184–186.PubMedGoogle Scholar
  235. Phillips, C. A., Forsyth, B. R., Christmas, W. A., et al., 1970, Purified influenza vaccine: Clinical and serologic responses to varying doses and different routes of immunization, J. Infect. Dis. 122:26–32.PubMedCrossRefGoogle Scholar
  236. Poser, C. M., Roman, G., and Emery, E. S. III, 1978, Recurrent disseminated vasculomyelinopathy, Arch. Neurol 35:166–170.PubMedCrossRefGoogle Scholar
  237. Potter, C. W., Oxford, J. S., Shore, S. L., et al., 1972, Immunity to influenza in ferrets. I. Response to live and killed virus, Br. J. Exp. Pathol. 53:153–167.PubMedGoogle Scholar
  238. Powers, R. D., Hayden, F. G., Samuelson, J., et al., 1984, Immune response of adults to sequential influenza vaccination, J. Med. Virol. 14:169–175.PubMedCrossRefGoogle Scholar
  239. Quarles, J. M., Couch, R. B., Cate, T. R., et al., 1981, Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza, Antivir. Res. 1:149–155.PubMedCrossRefGoogle Scholar
  240. Quinnan, G. V., Schooley, R., Dolin, R., et al., 1983, Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines, Rev. Infect. Dis. 5:748–757.PubMedCrossRefGoogle Scholar
  241. Ratner, E. R., and Fedson, D. S., 1983, Influenza and pneumococcal immunization in medical clinics, 1978–1980, Arch. Intern. Med. 143:2066–2069.PubMedCrossRefGoogle Scholar
  242. Reeve, P., Pibermann, M., Bachmayer, H., et al., 1982, Studies in man with a cold-recombinant live influenza B virus vaccine, J. Med. Virol. 9:1–9.PubMedCrossRefGoogle Scholar
  243. Reiss, C. S., and Schulman, J. L., 1980, Cellular immune responses of mice to influenza virus vaccines,J.. Immunol. 125:2182–2188.PubMedGoogle Scholar
  244. Renton, K. W., Gray, J. D., and Hall, R. I., 1980, Decreased elimination of theophylline after influenza vaccination, Can. Med. J. 123:288–290.Google Scholar
  245. Riddiough, M. A., Sisk, J. E., and Bell, J. C., 1983, Influenza vaccination. Cost-effectiveness and public policy, J.A.M.A. 249:3189–3195.PubMedCrossRefGoogle Scholar
  246. Rodda, S. J., Gallichio, H. A., and Hampson, A. W., 1981, The single radial immunodiffusion assay highlights small antigenic differences among influenza virus hemagglutinins, J. Clin. Microbiol. 14:479–482.PubMedGoogle Scholar
  247. Rogers, G. N., Daniels, R. S., Skehel, J. J., et al., 1985, Host-mediated selection of influenza virus receptor variants, J. Biol. Chem. 260:7362–7367.PubMedGoogle Scholar
  248. Rose, H. J., 1980, The use of amantadine and influenza vaccine in a type A influenza epidemic in a boarding school, J. R. Coll. Gen. Pract. 30:619–621.PubMedGoogle Scholar
  249. Rosen, C. M., Roman, G., and Emery, E. S. III, 1978, Recurrent disseminated vasculomyelinopathy, Arch. Neurol. 35:166–170.CrossRefGoogle Scholar
  250. Rosenzweig, D. Y., Dwyer, D. J., Ferstenfeld, J. E., et al., 1975, Changes in small airway function after live attenuated influenza vaccination, Am. Rev. Respir. Dis. 111:399–403.PubMedGoogle Scholar
  251. Rott, R., Becht, H., and Oflich, M., 1974, The significance of influenza virus neuraminidase in immunity, J. Gen. Virol 22:35–41.PubMedCrossRefGoogle Scholar
  252. Ruben, F. L., Potter, C. W., and Stuart-Harris, C. H,, 1975, Humoral and secretory antibody responses to immunization with low and high dosage split influenza virus vaccine, Arch. Virol 47:157–166.PubMedCrossRefGoogle Scholar
  253. Rytel, M. W., Jackson, L. J., Ferstenfeld, J. E., et al., 1975, New live attenuated influenza A/En-gland/42/72JH3N2) vaccine (“Alice”) reactogenicity, immunogenicity, and protection efficacy, J. Infect. Dis. 132:652–659.PubMedCrossRefGoogle Scholar
  254. Sabin, A. B., 1977, Swine flu: What happened. Sciences 17:14–30.Google Scholar
  255. Salk, J. E., 1948, Reactions to concentrated influenza vaccines, J. Immunol. 58:369–395.PubMedGoogle Scholar
  256. Salk, J. E., Bailey, M. L., and Laurent, A. M., 1952, The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water-in-oil emulsion, Am. J. Hyg. 55:439.PubMedGoogle Scholar
  257. Schiff, G. M., Linnemann, C. C., Shea, L., et al., 1975, Evaluation of a live, attenuated recombinant influenza vaccine in high school children, Infect. Immun. 11:754–757.PubMedGoogle Scholar
  258. Schoenbaum, S. C., 1979, Influenza vaccine-unacceptable or unaccepted, Am. J. Public Health 69:219–221.PubMedCrossRefGoogle Scholar
  259. Schoenbaum, S. C., McNeil, B. J., and Kavet, J., 1976, The swine-influenza decision, N. Engl. J. Med. 295:759–765.PubMedCrossRefGoogle Scholar
  260. Scholtissek, C., Vallbracht, A., Flehmig, B., et al., 1979, Correlation of pathogenicity and gene constellation of influenza A viruses. II. Highly neurovirulent recombinants derived from non-neurovirulent or weakly neurvirulent parent virus strains, Virology 95:492–500.PubMedCrossRefGoogle Scholar
  261. Schonberger, L. B., Bregman, D. J., Sullivan-Bolyai, J. Z., et al., 1979, Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977, Am. J. Epidemiol 110:105–123.PubMedGoogle Scholar
  262. Schulman, J. L., 1967, Experimental transmission of influenza virus infection in mice. III. Differing effects of immunity induced by infection and by inactivated influenza virus vaccine on transmission of infection, J. Exp. Med. 125:467–478.PubMedCrossRefGoogle Scholar
  263. Schulman, J. L., 1975, Immunology of influenza, in: The Influenza Viruses and Influenza (E. D. Kilbourne, ed.), Academic Press, New York, pp. 373–390.Google Scholar
  264. Schulman, J. L., and Kilbourne, E. D., 1971, Correlated studies of a recombinant influenza-virus vaccine. II. Definition of antigenicity in experimental animals, J. Infect. Dis. 124:463–472.PubMedCrossRefGoogle Scholar
  265. Schulman, J. L., and Palese, P., 1978, Biological properties of recombinants of A/Hong Kong and A/PR8 viruses: Effects of genes for matrix protein and nucleoprotein in virus yield in embryonated eggs, in: Negative Strand Viruses and the Host Cell (B. W. J. Mahy and R. D. Barry, eds.), Academic Press, New York, pp. 663–674.Google Scholar
  266. Schulman, J. L., Khakpour, M., and Kilbourne, E. D., 1968, Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice, J. Virol. 2:778–786.PubMedGoogle Scholar
  267. Schutze, M.-P., Lerclerc, C., Jolivet, M., et al., 1985, Carrier-induced epitopic suppression, a major issue for future synthetic vaccines, J. Immunol. 135:2319–2322.PubMedGoogle Scholar
  268. Serie, C., Barme, M., Hannoun, C., et al., 1977, Effects of vaccination on an influenza epidemic in a geriatic hospital, Dev. Biol. Stand. 39:317–321.PubMedGoogle Scholar
  269. Seyal, M., Ziegler, D. K., and Couch, J. R., 1978, Recurrent Guillain-Barre syndrome following influenza vaccine, Neurology (Minneap.) 28:725–726.CrossRefGoogle Scholar
  270. Shapira, M., Jibson, M., Muller, G., et al., 1984, Immunity and protection against influenza virus by synthetic peptide corresponding to antigenic sites of hemagglutinin, Proc. Natl. Acad. Sci. U.S.A. 81:2461–2465.PubMedCrossRefGoogle Scholar
  271. Sheps, S. B., Mathias, R. G., Wilson, R., et al., 1985, Influenza vaccine utilization in a metropolitan health department: supply side constraints, Can. J. Public Health 76:378–383.PubMedGoogle Scholar
  272. Shore, S. L., Potter, C. W., and Stuart-Harris, C. H., 1973, Antibody response to inactivated influenza vaccine given by different routes in patients with chronic bronchopulmonary disease, Thorax 28:721–728.PubMedCrossRefGoogle Scholar
  273. Siegert, R., and Braune, P., 1964, The pyrogens of myxoviruses. II. Resistance of influenza A pyrogens to heat, ultraviolet and chemical treatment, Virology 24:218–224.PubMedCrossRefGoogle Scholar
  274. Silverstein, A. M., 1981, Pure Politics and Impure Science ,The Johns Hopkins University Press, Baltimore, London.Google Scholar
  275. Slepushkin, A. N., Ellengorn, N. S., Russina, A. E., et al., 1968, Assessment of the efficacy of mass influenza vaccinations. [Assessment of the efficacy of mass influenza vaccinations. Report II], (English summary), J. Microbiol. Epidemiol. Immunobiol. 10:26–32.Google Scholar
  276. Smith, G. L., Murphy, B. R., and Moss, B., 1983, Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters, Proc. Natl. Acad. Sci. U.S.A. 80:7155–7159.PubMedCrossRefGoogle Scholar
  277. Smith, J. W. G., and Pollard, R., 1979, Vaccination against influenza: A five-year study in the Post Office, J. Hyg. (Camb.) 83:157–170.CrossRefGoogle Scholar
  278. Smorodintsev, A. A., Tushinsky, M. D., Drobyshevskaya, A. I., et al., 1937, Investigation on volunteers infected with influenza virus, Am. J. Med. Sci. 194:159–170.CrossRefGoogle Scholar
  279. Smorodintsev, A. A., Mikutskaya, B. A., Alexandrova, G. I., 1967, Data on safety and epidemiological efficiency of anti-influenza vaccine studied on pre-school children, J. Hyg. Epidemiol. Microbiol. Immunol. 11:265–277.PubMedGoogle Scholar
  280. Smorodintsev, A. A., Karpuhin, G. I., Zlydnikov, D. M., et al., 1970, The prophylactic effectiveness of amantadine hydrochloride in an epidemic of Hong Kong influenza in Leningrad in 1969, Bull. 42:865–872.Google Scholar
  281. Soloviev, V. D., Orlova, T. G., Porubel, L. A., et al., 1961, Study of the genetic characters of vaccine strains of type A-2 influenza virus, Prob. Virol. 6:743–750.Google Scholar
  282. Spencer, M. J., Cherry, J. D., and Terasaki, P. I., 1976, HL-A antigens and antibody response after influenza A vaccination, N. Engl. J. Med. 294:13–16.PubMedCrossRefGoogle Scholar
  283. Spring, S. B., Maassab, H. F., Kendal, A. P., et al., 1977, Arch. Virol. 55:233–246.PubMedCrossRefGoogle Scholar
  284. Steinberg, E., Overturf, G. D., Portnoy, B., et al., 1978, Serologic and clinical response of children with sickle cell disease to bivalent influenza A split virus vaccine, J. Pediatr. 92:823–825.PubMedCrossRefGoogle Scholar
  285. Steinherz, P. G., Brown, A. E., Gross, P. A., et al., 1980, Influenza immunization of children with neoplastic diseases, Cancer 45:750–756.PubMedCrossRefGoogle Scholar
  286. Stewart-Tull, D. E. S., 1985, Immunopotentiating conjugates, Vaccine 3:40–44.PubMedCrossRefGoogle Scholar
  287. Stiver, H. G., and Weinerman, B. H., 1978, Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients, Can. Med. Assoc. J. 119:733–735.PubMedGoogle Scholar
  288. Stiver, H. G., Graves, P., Eickhoff, T. C., et al., 1973, Efficacy of “Hong Kong” vaccine in preventing “England” variant influenza A in 1972, N. Engl. J. Med. 289:1267–1271.PubMedCrossRefGoogle Scholar
  289. Storms, W. W., Dick, E. C., and Busse, W. W., 1976, Intranasal immunization with attenuated live influenza vaccine in asthma, J. Allergy Clin. Immunol. 58:284–290.PubMedCrossRefGoogle Scholar
  290. Takafuji, E. T., Johnson, D. E., and Segal, H. E., 1976, The swine antigen in previous influenza vaccines, N. Engl. J. Med. 295:1018.PubMedGoogle Scholar
  291. Tian, S., Zhang, L., and Murphy, B. R., 1984, Characterization of the genotype and level of attenuation of an influenza A reassortant virus produced by mating the Xia-ts donor virus with AJ.Beij-ing/79 (H1N1) wild type virus, Vaccine 2:189–192.PubMedCrossRefGoogle Scholar
  292. Tian, S.-F., Buckler-White, A. J., London, W. T., et al., 1985, Nucleoprotein and membrane protein genes are associated with restriction of replication of influenza A/Mallard/NY/78 virus and its reas-sortants in squirrel monkey respiratory tract, J.. Virol. 53:771–775.PubMedGoogle Scholar
  293. Tolpin, M. D., Massicot, J. G., Mullinix, M. G., et al., 1981, Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-lA2 recombinant during growth in vivo, Virology 112:505–517.PubMedCrossRefGoogle Scholar
  294. Tolpin, M. D., Clements, M. L., Levine, M. M., et al., 1982, Evaluation of a phenotypic revertant of the A/Alaska/77-ts-lA2 reassortant virus in hamsters and in seronegative adult volunteers: Further evidence that the temperature-sensitive phenotype is responsible for attenuation of ts-lA2 reassortant viruses, Infect. Immun. 36:645–650.PubMedGoogle Scholar
  295. Top. F. H., Jr., and Russell, P. K., 1977, Swine influenza A at Fort Dix, New Jersey (January-February 1976), IV. Summary and speculation, J. Infect. Dis. 136:S376–S379.PubMedCrossRefGoogle Scholar
  296. van de Donk, H. J. M., de Jong, J. C., van Olderen, M. F., et al., 1984, Monoclonal antibodies for the control of influenza virus vaccines, Dev. Biol. Stand. 57:251–255.PubMedGoogle Scholar
  297. Versluis, D. J., Beyer, W. E. P., Masurel, N., et al., 1985, Influenza vaccination in dialysis and transplant patients, Antiviral Res. (Suppl.) 1:289–292.Google Scholar
  298. Wabuke-Bunoti, M. A. N., Taku, A., Fan, D. P., et al., 1984, Cytolytic T lymphocyte and antibody responses to synthetic peptides of influenza virus hemagglutinin, J. Immunol. 133:2194–2201.PubMedGoogle Scholar
  299. Wagner, R. R., Bennett, I. L., Jr., and LeQuire, V. S., 1949, The production of fever by influenzal viruses. I. Factors influencing the febrile response to single injections of virus, J. Exp. Med. 90:321–334.PubMedCrossRefGoogle Scholar
  300. Waldman, R. H., Mann, J. J., and Small, P. A., Jr., 1969a, Immunization against influenza, J.A.M.A. 207:520–524.PubMedCrossRefGoogle Scholar
  301. Waldman, R. H., Bond, J. O., Levitt, L. P., et al., 1969b, An evaluation of influenza immunization, Bull. WHO 41:543–548.PubMedGoogle Scholar
  302. Waldman, R. H., Wood, S. H., Torres, E. J., et al., 1970, Influenza antibody response following aerosol administration of inactivated virus, Am. J. Epidemiol. 94:575–584.Google Scholar
  303. Waksman, B. H., and Adams, R. D., 1955, Allergic neuritis: An experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants, J. Exp. Med. 102:213–235.PubMedCrossRefGoogle Scholar
  304. Warburton, M. F., Jacobs, D. S., Langsford, W. A., et al., 1972, Herd immunity following subunit influenza vaccine administration, Med. J. Aust. 2:67–70.PubMedGoogle Scholar
  305. Watson, W. H., Parks, M., Porter, D. A., et al., 1972, Influenza vaccination in schoolboys, Lancet 1:1336.PubMedCrossRefGoogle Scholar
  306. Webster, R. G., 1966, Original antigenic sin in ferrets: The response to sequential infections with influenza viruses, J. Immunol. 97:177–183.PubMedGoogle Scholar
  307. Webster, R. G., and Askonas, B. A., 1980, Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice, Eur. J. Immunol. 10:396–401.PubMedCrossRefGoogle Scholar
  308. Webster, R. G., Kasel, J. A., Couch, R. B., et al., 1976, Influenza virus subunit vaccines. II. Immunoge-nicity and original sin in humans, J. Infect. Dis. 134:48–58.PubMedCrossRefGoogle Scholar
  309. Webster, R. G., Kawaoka, Y., Bean, W. J., et al., 1985, Chemotherapy and vaccination: A possible strategy for the control of highly virulent influenza virus, J. Virol. 55:173–176.PubMedGoogle Scholar
  310. Weibel, R. E., McLean, A., Woodhour, A. F., et al., 1973, Ten-year follow-up study for safety of adjuvant 65 influenza vaccine in man, Proc. Soc. Exp. Biol. Med. 143:1053–1056.PubMedGoogle Scholar
  311. Weintraub, M. I., and Chia, D. T. S., 1977, Paralytic brachial neuritis after swine flu vaccination, Arch. Neurol. 34:518.PubMedCrossRefGoogle Scholar
  312. Wenzel, R. P., Hendley, O., Sande, M. A. et al., 1973, Revised (1972–1973) bivalent influenza vaccine, J.A.M.A. 226:435–438.PubMedCrossRefGoogle Scholar
  313. Wesselius-de Casparis, A., Hogerzeil, H. H. W., and van Beek, A., 1973, Eleven years of experiences in industry with vaccination against influenza: Reduction in absenteeism, in: International Symposium on Influenza Vaccines for Men and Horses, London, 1972 (Symposium Series Immunobiology Standard ,Vol. 20), S. Karger, Basel, pp. 268–274.Google Scholar
  314. Wiederholt, W. C., Mulder, D. W., and Lambert, E. H., 1964, The Landry Guillain-Barre-Strohl syndrome or polyradiculoneuropathy: Historical review, report on 97 patients, and present concepts, Mayo Clin. Proc. 39:427–451.PubMedGoogle Scholar
  315. Wiley, D. C., Wilson, I. A., and Skehel, J. J., 1981, Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation, Nature 289:373–378.PubMedCrossRefGoogle Scholar
  316. Wilson, I. A., Niman, H. L., Houghten, R. A., et al., 1984, The structure of an antigenic determinant in a protein, Cell 37:767–778.PubMedCrossRefGoogle Scholar
  317. Wood, J. M., Schild, G. C., Newman, R. W., et al., 1977, An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole virus and subunit vaccines, J. Biol. Stand. 5:237–247.PubMedCrossRefGoogle Scholar
  318. Wood, J. M., Seagroatt, V., Schild, G. C., et al., 1981, International collaborative study of single-radial-diffusion and Immunoelectrophoresis techniques for the assay of haemagglutinin antigen of influenza virus, J. Biol. Stand. 9:317–330.PubMedCrossRefGoogle Scholar
  319. Woodhour, A. F., Friedman, A., Tytell, A. A., et al., 1969, Hyperpotentiation by synthetic double-stranded RNA of antibody responses to influenza virus vaccine in adjuvant 65, Proc. Soc. Exp. Biol. Med. 131:809–817.PubMedGoogle Scholar
  320. World Health Organization, 1985, Recombinant vaccinia viruses as live virus vectors for vaccine antigens: Memorandum from a WHO/USPHS/NIBSC Meeting, Bull. WHO 63:471–477.Google Scholar
  321. Wright, P. F., Sell, S. H. W., Thompson, J., et al., 1976, Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants, J. Pediatr. 88:31–35.PubMedCrossRefGoogle Scholar
  322. Wright, P. F., Bhargava, M., Johnson, P. R., et al., 1985, Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes, Vaccine 3:305–308.PubMedCrossRefGoogle Scholar
  323. Yamane, N., Nakamura, Y., Yuki, M., et al., 1984, Serological evaluation of an influenza A virus cold-adapted reassortant live vaccine, CR-37 (H1N1) in Japanese adult volunteers, J. Hyg. (Camb.) 92:231–242.CrossRefGoogle Scholar
  324. Zahradnik, J. M., Kasel, J. A., Martin, R. R., et al., 1983, Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine, J. Med. Virol. 11:277–285.PubMedCrossRefGoogle Scholar
  325. Zeck, R., Solliday, N., Kehoe, T., et al., 1976, Respiratory effects of live influenza virus vaccine: Healthy older subjects and patients with chronic respiratory disease, Am. Rev. Respir. Dis. 114:1061–1067.PubMedGoogle Scholar

Copyright information

© Edwin D. Kilbourne, M.D. 1987

Authors and Affiliations

  • Edwin D. Kilbourne
    • 1
  1. 1.Mount Sinai School of MedicineCity University of New YorkNew YorkUSA

Personalised recommendations